SSKN Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $6.9 million, down 20% year-over-year, primarily due to challenges in international markets.

Recurring Revenue: Global recurring revenue was $5.5 million, up 3% year-over-year. U.S. recurring XTRAC revenue increased by 2.8%.

Equipment Revenue: $1.4 million, a significant decrease of 60% compared to the prior year.

Gross Profit: $4.2 million, maintaining a gross margin of 60%, consistent with the previous year.

Operating Expenses: Reduced to $5.4 million from $6.9 million, largely due to a one-time sales tax accrual in 2024.

Net Loss: $1.6 million, or EPS of -$0.36, improved from a net loss of $2.1 million or EPS of -$0.51 in 2024.

Adjusted EBITDA: Slightly positive compared to -$240,000 in the same quarter last year.

Cash Position: Cash and cash equivalents stood at $7.1 million as of September 30, 2025.

2Strategic Updates and Business Highlights

CPT Code Expansion: Anticipated expansion of CPT codes for the XTRAC laser effective January 1, 2027, broadening reimbursement eligibility to over 30 million patients and tripling the addressable market.

Elevate360 Program: 99 out of 838 partner clinics have adopted this program, resulting in an average 7% revenue growth for participating clinics.

International Expansion: Initial commercial placements of TheraClear in Mexico following regulatory approval, with plans for further growth in the region.

Litigation Update: Ongoing case against LaserOptik, with potential for significant damages and a positive injunction limiting further damage to STRATA's business.

3Forward Guidance and Outlook

Q4 Expectations: Management anticipates a seasonally stronger fourth quarter in 2025, driven by expanded patient population and favorable reimbursement trends.

Growth Potential: Continued focus on increasing average revenue per device from $6,000 to $7,500 could yield an additional $5 million in revenue.

4Challenges and Points of Concern

International Business Headwinds: Ongoing challenges attributed to U.S. trade policy affecting international revenue.

Declining Equipment Revenue: A significant drop in equipment sales raises concerns about future capital investments and growth.

Litigation Risks: While there is potential for recovery, the company remains exposed to competitive pressures and market uncertainties stemming from false claims by competitors.

5Notable Q&A Insights

Average Revenue per Device: Increased to $5,981, the highest since 2022, driven by improved utilization and removal of non-productive devices.

DTC Campaign Success: Improved patient show-up rates and lower acquisition costs noted, contributing to better overall financial performance.

Future Device Installations: Anticipated growth in TheraClear installations, with a target of reaching approximately 200 devices by the end of 2025.

Temporary Codes for 2026: CMS has decided against creating temporary codes for 2026, focusing instead on the established codes set to take effect in 2027. Overall, STRATA Skin Sciences is navigating a challenging environment but is strategically positioned for growth through expanded market opportunities and operational improvements.